Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aligastril
- Development stage
- Unknown
- Lead developer
- Laboratori Aliveda
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Aligastril is a multi-ingredient dietary supplement developed by Laboratori Aliveda for the management of gastritis, hyperacidity, functional dyspepsia, NSAID-induced gastropathy, and gastroesophageal reflux disease (GERD). It is available in two oral formulations: a ready-to-use gel and a dissolvable powder. The synergistic formulation combines sodium alginate, melatonin, and chamomile extract, with the powder version also containing sodium bicarbonate and chitosan. Sodium alginate reacts with gastric acid to form a viscous gel raft that floats on top of the stomach contents, creating a physical barrier that mechanically prevents acid reflux. Melatonin stimulates gastrin release to increase lower esophageal sphincter (LES) tone, inhibits gastric acid secretion, and promotes mucosal healing. Chamomile extract provides soothing, anti-inflammatory, and spasmolytic effects on the gastrointestinal tract, while sodium bicarbonate acts as a rapid antacid to neutralize excess stomach acid.
- Brand names
- AligastrilAligastril Gel
- Other names
- Aligastril gelAligastril powder
02
Targets
MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)
Beyond the preview
Go deeper on Aligastril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aligastril.